Contents 4 dk okuma
Important Note
This page is not medical advice. Vinpocetine has prescription drug status in some countries; Consult a healthcare professional before use. It should not be used during pregnancy.
What is Vinpocetine?
vinpocetine, vinca minor It is a semi-synthetic derivative of the natural alkaloid vincamine obtained from the (little periwinkle) plant and was developed by Gedeon Richter company in Hungary in 1978. It is available by prescription in more than 35 countries, especially in Hungary, Germany and Russia, under the brands "Cavinton" and "Kavinton".
Although it is not approved as a drug by the FDA in the United States, it is sold as a food supplement. In Western Europe, it has a status that varies depending on the country. This unclear legal status often leads to confusion about vinpocetine; It is recommended that you check the legal situation in your country before use.
Mechanism of Effect
The cognitive effects of vinpocetine are explained by multiple mechanisms. Although its main effect is at the cerebral vascular level, there are also neurochemical and neuroprotective contributions.
PDE1 (Phosphodiesterase-1) inhibition: Vinpocetine selectively inhibits the PDE1 enzyme, which breaks down cAMP and cGMP. This effect leads to smooth muscle relaxation, vasodilation in the brain vessels and increased cerebral blood flow. Increased blood flow allows more oxygen and glucose to reach the brain tissue.
Sodium channel inhibition: Vinpocetine reduces neuronal hyperexcitability and reduces the risk of neurotoxicity by mildly blocking voltage-gated sodium channels. This mechanism is similar to the mode of action of antiepileptic drugs.
Increased brain glucose metabolism: It has been observed in PET and SPECT studies that vinpocetine use increases cerebral glucose utilization. This effect is especially evident in post-ischemia regions.
| mechanism | Impact | evidence |
|---|---|---|
| PDE1 inhibition | Cerebral vasodilation, increased blood flow | Strong |
| Na+ channel blockade | Neuroprotection, epileptic discharge reduction | medium |
| Increased glucose metabolism | Brain energy efficiency improvement | medium |
| NF-κB inhibition | Reduced neuroinflammation | Low-Medium |
Clinical Evidence
Hindmarch et al. (1991)demonstrated that use of 3 × 10 mg vinpocetine significantly improved memory test performance in a double-blind placebo-controlled study in 203 healthy elderly participants. The effect is particularly evident in short-term memory and cognitive processing speed.
Subhan and Hindmarch (1985)reported that vinpocetine improved memory processes (both at the encoding and retrieval stages) in healthy volunteers in a double-blind crossover design study. The effect magnitude was found to be moderate compared to similar vasoactive agents.
Studies conducted in the field of rehabilitation after cerebral ischemia and transient ischemic attack (TIA) have demonstrated stronger results; However, most of these studies have methodological limitations.
⚠ Research and Legal Limitations
The evidence base for vinpocetine is more limited compared to Ginkgo Biloba or Bacopa Monnieri. In the USA, the FDA questioned its status as a food supplement in 2019 on the grounds of "synthetic derivative". It should never be used during pregnancy as negative results have been reported in animal studies.
Dosage Protocol
Vinpocetine is fat-soluble and its bioavailability increases significantly when taken with meals. Since its half-life is short, it is preferable to divide the daily dose into three.
| Intended Use | Dose | Timing |
|---|---|---|
| Starting dose | 5 mg × 3 per day | At every meal, with food |
| standard dose | 10 mg × 3 per day | with food |
| Clinical study dose | 20 mg × 3 per day | Under doctor's supervision |
Safety and Side Effects
- Headache: The most frequently reported side effect; caused by vasodilation.
- Nausea: Especially when taken on an empty stomach; It largely prevents intake with meals.
- Blood pressure drop: Due to its vasodilator effect, caution should be exercised in hypotensive individuals.
- Mild blood thinning: It may reduce platelet aggregation; Be careful in those with coagulation problems.
Who Does It Interact With?
- Anticoagulants and antiplatelet drugs (warfarin, aspirin): Synergistic blood thinning effect; Use with caution.
- Antihypertensives: It may potentiate the blood pressure lowering effect.
- Ginkgo Biloba: Caution should be exercised when combining as both increase cerebral blood flow.
- Caffeine: Concomitant use is common; No major interactions have been reported.
Sources
- Hindmarch I, et al. (1991). Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. International Clinical Psychopharmacology, 6(1), 31–43. PubMed · PMID 2071888
- Subhan Z & Hindmarch I (1985). Psychopharmacological effects of vinpocetine in normal healthy volunteers. European Journal of Clinical Pharmacology, 28(5), 567–571. PubMed · PMID 3899677
- Bereczki D & Fekete I (2008). Vinpocetine for acute ischaemic stroke. Cochrane Database of Systematic Reviews, (1), CD000480. PubMed · PMID 18253980
- Valikovics A (2007). Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions. Ideggyogy Sz, 60(7–8), 301–310. PubMed · PMID 17713111
- Kemeny V, et al. (2005). Vinpocetine increases cerebral blood flow and attenuates cognitive decline in patients with chronic cerebrovascular disease. Clinical Drug Investigation, 25(8), 525–534. Search PubMed (match unverified)
Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory
Frequently Asked Questions
Vinpocetine is a vasoactive nootropic that increases cerebral blood flow. It dilates brain vessels by inhibiting the PDE1 enzyme, thus allowing more oxygen and glucose to reach the brain. Its positive effects on cognitive clarity, focus and short-term memory have been supported by clinical studies. It differs from other nootropics especially with its rapid onset of action (30–60 minutes).
The recommended starting dose is 5 mg three times a day. After assessing tolerance, the standard dose can be switched to 10 mg 3 times a day. 20 mg three times a day has been used in clinical studies, but this dose requires physician supervision. Since vinpocetine is fat-soluble, it should be taken with meals to increase its bioavailability. Due to its short half-life (2–3 hours), the daily dose should be divided into three.
The most frequently reported side effect is headache due to vasodilation. This is followed by nausea; This effect is especially seen when taken on an empty stomach and is largely prevented by taking it with food. Due to its vasodilator effect, caution should be exercised in people with low blood pressure. Additionally, since it may reduce platelet aggregation, it should not be used by those using blood thinners, those with coagulation disorders and during pregnancy.
Vinpocetine has prescription drug status in Türkiye under brands such as Cavinton and Kavinton. It can be obtained from pharmacies only with a doctor's prescription. It is not available for free sale as a food supplement. Importation of foreign supplement forms into Türkiye remains in a legally uncertain area. It is recommended to consult a physician or pharmacist before use.
Vinpocetine begins to show its effect within approximately 30–60 minutes after oral administration. Since its half-life is 2–3 hours, the effect of a single dose is relatively short-lived; Therefore, intake 3 times a day is preferred. While effects on cerebral blood flow begin quickly, cumulative benefits on memory and cognitive performance may become more apparent over several weeks of regular use.
